Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Cancer and fibrosis focused Redx Pharma said it had successfully completed dosing of the first cohort of patients in an ongoing cancer treatment study.
The company said a safety review committee had recommended that the dose of the treatment candidate -- RXC004 -- could now be escalated.
Consequently, recruitment of a second patient cohort, who will be administered the drug at a higher pre-specified dose, had begun as per the trial protocol.
RXC004 was an oral porcupine inhibitor targeting the Wnt signalling pathway, with the potential to be developed in different cancers and in different treatment settings. 'We believe that RXC004 has the potential to offer clinical benefit both as a monotherapy and in combination with standard of care treatments for patients with Wnt-driven advanced solid tumours,' chief executive Lisa Anson said.
'We look forward to completing patient enrolment for the phase 1 monotherapy dose-escalation study and to announcing results during 2020.'